Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.57 |
| ▸ | LDHA | P00338 | 1/20 | 0.57 |
| ▸ | GRM8 | O00222 | 1/20 | 0.55 |
| ▸ | GRM6 | O15303 | 1/20 | 0.55 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.52 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | TPH1 | P17752 | 2/20 | 0.49 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.49 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.49 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.49 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.49 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.49 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.49 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6942606 | 1.00 | KIF11 (0.57) | KIF11LDHAGRM8GRM6GRM4 | |
| SCHEMBL18071078 | 1.00 | KIF11 (0.57) | KIF11LDHAGRM8GRM6GRM4 | |
| SCHEMBL2926805 | 0.90 | KIF11 (0.55) | KIF11LDHAGRM8GRM6GRM4 | |
| SCHEMBL1238414 | 0.90 | KIF11 (0.55) | KIF11LDHAGRM8GRM6GRM4 | |
| SCHEMBL28463183 | 0.90 | KIF11 (0.55) | KIF11LDHAGRM8GRM6GRM4 | |
| SCHEMBL28463903 | 0.89 | KIF11 (0.53) | KIF11LDHAGRM8GRM6GRM4 | |
| SCHEMBL10419544 | 0.89 | KIF11 (0.53) | KIF11LDHAGRM8GRM6GRM4 | |
| SCHEMBL28463907 | 0.89 | KIF11 (0.53) | KIF11LDHAGRM8GRM6GRM4 | |
| SCHEMBL10420495 | 0.88 | KIF11 (0.52) | KIF11LDHAGRM8GRM6GRM4 | |
| SCHEMBL28467284 | 0.88 | KIF11 (0.52) | KIF11LDHAGRM8GRM6GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171495-A1 | MUTLI-TARGETED SERINE PROTEASE INHIBITORS FOR TREATMENT OF CANCER AND VIRAL INFECTION | WASHINGTON UNIVERSITY | 2025-05-29 | — | — | US | claimed |
| US-20220380407-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, VIRAL INFECTIONS, AND ALLERGIC CONDITIONS | WASHINGTON UNIVERSITY (US) | 2022-12-01 | — | — | US | claimed |
| EP-3989997-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, VIRAL INFECTIONS, AND ALLERGIC CONDITIONS | Washington University (US) | 2022-05-04 | — | — | EP | claimed |
| US-12590123-B2 | Compounds and methods for treating cancer, viral infections, and allergic conditions | WASHINGTON UNIVERSITY (US) | 2026-03-31 | — | — | US | disclosed |
| US-20250171495-A1 | MUTLI-TARGETED SERINE PROTEASE INHIBITORS FOR TREATMENT OF CANCER AND VIRAL INFECTION | WASHINGTON UNIVERSITY | 2025-05-29 | — | — | US | disclosed |
| EP-4433495-A1 | PEPTIDES AND USES THEREOF | Preveceutical Medical Inc. (CA) | 2024-09-25 | — | — | EP | disclosed |
| US-20240301023-A1 | PEPTIDES AND USES THEREOF | PreveCeutical Medical Inc. (CA) | 2024-09-12 | — | — | US | disclosed |
| WO-2024148312-A1 | COMPOSITIONS, SYSTEMS, AND METHODS FOR AMINO ACID SYNTHESIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-07-11 | — | — | WO | disclosed |
| US-11732007-B2 | Therapeutic compounds and methods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-22 | — | — | US | disclosed |
| WO-2023089542-A1 | PEPTIDES AND USES THEREOF | PreveCeutical Medical Inc. (CA) | 2023-05-25 | — | — | WO | disclosed |
| US-20220380407-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, VIRAL INFECTIONS, AND ALLERGIC CONDITIONS | WASHINGTON UNIVERSITY (US) | 2022-12-01 | — | — | US | disclosed |
| EP-3191113-B1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80 (B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL MYERS SQUIBB CO (US) | 2019-11-06 | — | — | EP | disclosed |
| US-10344060-B2 | Potent and selective inhibitors of Nav1.7 | AMGEN INC. (US) | 2019-07-09 | — | — | US | disclosed |
| EP-2970408-B1 | POTENT AND SELECTIVE INHIBITORS OF NAV1.7 | AMGEN INC (US) | 2018-01-10 | — | — | EP | disclosed |
| US-20160024159-A1 | POTENT AND SELECTIVE INHIBITORS OF NAV1.7 | AMGEN INC. (US) | 2016-01-28 | — | — | US | disclosed |
| EP-2970408-A2 | POTENT AND SELECTIVE INHIBITORS OF Nav1.7 | Amgen Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014165277-A2 | POTENT AND SELECTIVE INHIBITORS OF Nav1.7 | AMGEN INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| EP-0902011-B1 | GAMMA-OXO-HOMOPHENYLALANINE DERIVATIVES AND PROCESS FOR PRODUCING HOMOPHENYLALANINE DERIVATIVES BY REDUCING THE SAME | KANEKA CORP (JP) | 2003-05-21 | — | — | EP | disclosed |
| US-5981794-A | REACTING A BETA-BENZOYLACRYLIC ACID DERIVATIVE WITH A 1-ARYLETHYLAMINE DERIVATIVE | KANEKA CORPORATION (JP) | 1999-11-09 | — | — | US | disclosed |
| EP-0902011-A1 | $g(g)-OXO-HOMOPHENYLALANINE DERIVATIVES AND PROCESS FOR PRODUCING HOMOPHENYLALANINE DERIVATIVES BY REDUCING THE SAME | Kaneka Corporation (JP) | 1999-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240301023-A1 | PEPTIDES AND USES THEREOF | OPRL1, OPRK1, OPRM1 | KIF11 1440/4885LDHA 2547/4885GRM8 466/4885 |
| US-10344060-B2 | Potent and selective inhibitors of Nav1.7 | SCN7A, SCN9A, SCN1A | KIF11 3091/4885LDHA 3800/4885GRM8 745/4885 |
| US-12590123-B2 | Compounds and methods for treating cancer, viral infections, and allergic conditions | TMPRSS2, TMPRSS4, F2RL3 | KIF11 3300/4885LDHA 650/4885GRM8 3280/4885 |
| US-20250171495-A1 | MUTLI-TARGETED SERINE PROTEASE INHIBITORS FOR TREATMENT OF CANCER AND VIRAL INFECTION | TMPRSS2, PRSS1, PRSS2 | KIF11 4208/4885LDHA 295/4885GRM8 3159/4885 |
| US-11732007-B2 | Therapeutic compounds and methods | MMP11, MMP13, MMP12 | KIF11 329/4885LDHA 1758/4885GRM8 3477/4885 |
| US-20220380407-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, VIRAL INFECTIONS, AND ALLERGIC CONDITIONS | TMPRSS2, PRSS1, PRSS2 | KIF11 1345/4885LDHA 602/4885GRM8 3438/4885 |
| US-20160024159-A1 | POTENT AND SELECTIVE INHIBITORS OF NAV1.7 | SCN7A, SCN9A, SCN1A | KIF11 3091/4885LDHA 3800/4885GRM8 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.